Related Experiment Video

Updated: May 7, 2026

A Mimic of the Tumor Microenvironment: A Simple Method for Generating Enriched Cell Populations and Investigating Intercellular Communication
09:52

A Mimic of the Tumor Microenvironment: A Simple Method for Generating Enriched Cell Populations and Investigating Intercellular Communication

Published on: September 20, 2016

Effect of an angiotensin II type 1 receptor blocker on caveolin-1 expression in prostate cancer cells

Agnieszka Wanda Piastowska-Ciesielska1, Marcin Kozłowski, Waldemar Wagner

  • 1Department of Comparative Endocrinology, Faculty of Biomedical Sciences and Postgraduate Training, Medical University of Lodz, Poland.

Archives of Medical Science : AMS
|September 20, 2013
PubMed
Abstract

Insights

Candesartan, an angiotensin II receptor blocker, significantly decreases caveolin-1 expression in metastatic prostate cancer cells. This finding may offer new therapeutic strategies for prostate cancer by targeting AT1 receptor signaling.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Caveolin-1 (Cav-1) is a key structural protein in caveolae, interacting with the angiotensin II type 1 receptor (AT1-R).
  • The role of Cav-1 in cancer is complex and context-dependent.
  • The AT1-R-caveolin complex may mediate angiotensin II (Ang II)-induced signaling pathways.

Purpose of the Study:

  • To investigate the impact of candesartan, an AT1-R blocker, on caveolin-1 expression in human metastatic prostate adenocarcinoma (PC-3) cells.
  • To explore the potential of AT1 receptor inhibitors in prostate cancer therapy.

Main Methods:

  • Cell viability and proliferation were assessed using WST-1 and BrdU assays.
  • Gene and protein expression levels of Cav-1 and AT1-R were analyzed using real-time RT-PCR and Western blot, respectively.
  • PC-3 cells were treated with Ang II and/or candesartan.

Main Results:

  • Candesartan treatment significantly decreased both caveolin-1 mRNA and protein expression in PC-3 cells compared to controls.
  • Angiotensin II treatment led to increased caveolin-1 mRNA and protein expression.
  • The study quantified significant changes in Cav-1 expression levels under different treatment conditions.

Conclusions:

  • Candesartan effectively reduces caveolin-1 expression in metastatic prostate cancer cells.
  • These findings contribute to understanding the mechanism of AT1 receptor inhibitors.
  • The results suggest potential therapeutic applications for candesartan in prostate cancer treatment.
Keywords:
angiotensin IIangiotensin II type 1 receptorcandesartancaveolin-1prostate cancer

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...